ethyl 2-(ethoxymethylene)-3-oxopentanoate | 16475-76-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 2-(ethoxymethylene)-3-oxopentanoate
• 英文别名: 3-Oxo-2-ethoxymethylen-pentansaeure-ethylester；ethyl 2-(ethoxymethylidene)-3-oxopentanoate
• CAS: 16475-76-6
• 化学式: C₁₀H₁₆O₄
• mdl: MFCD18905735
• 分子量: 200.235
• InChiKey: QXPMTJPDLMLQDR-UHFFFAOYSA-N

物化性质

• 沸点：
  285.8±30.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  ethyl 2-(ethoxymethylene)-3-oxopentanoate 在 吡啶 、 sodium hydroxide 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲醇 、 二苯醚 为溶剂， 反应 121.08h， 生成 1-(8-Hydroxymethyl-4-o-tolylamino-quinolin-3-yl)-propan-1-one
  参考文献：
  名称：

  Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 4. Identification of an Inhibitor with an Intermediate Duration of Action

  摘要：

  3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this series is developed. Only a limited range of substituents are tolerated on the N-aryl ring or the 6- and 7-positions of the quinoline, and although hydroxylated derivatives were identified possessing markedly greater affinity for the enzyme, none of these proved to have adequate potency after oral dosing. In contrast, the 8-position of the quinoline ring proved suitable for a wide variety of substituents, allowing modification of physicochemical properties while retaining primary activity. This led to the identification of compound 4 (SK&F 97574), which combines good oral potency with a somewhat longer duration of action than 3 (though much shorter than covalent inhibitors such as omeprazole). This compound was selected for further development and evaluation in man.

  DOI：

  10.1021/jm00014a026
• 作为产物：
  描述：

  原甲酸三乙酯 、 丙酰乙酸乙酯 在 乙酸酐 作用下， 以50%的产率得到ethyl 2-(ethoxymethylene)-3-oxopentanoate
  参考文献：
  名称：

  聚酮烯醇和螯合物。第一部分。黄原烯醇和黄嘌呤酮的形成与组成

  摘要：

  根据光谱和化学证据，提出了一种新结构，该结构是将乙二乙酸乙酸乙酯和乙氧基亚甲基乙酰乙酸乙酯一起加热时形成的黄色化合物二乙基黄体烯醇。概述并支持了形成机制。新的信息可用于制备各种an吨酮类化合物，其中3,3'，3'，5-四乙酰基-6-丙烯基-α-吡喃酮和3'-乙酰基-3,3'中的两个5-三乙氧基羰基-6-丙烯基-α-吡喃酮使结构上的竞争者被打折。

  DOI：

  10.1039/j39670000757

文献信息

• Polyketo-enols and chelates. Part I. The formation and constitution of xanthophanic enol and the xanthyrones
  作者：L. Crombie、D. E. Games、M. H. Knight

  DOI：10.1039/j39670000757

  日期：——

  A new structure is proposed, on the basis of spectroscopic and chemical evidence, for the yellow compound diethyl xanthophanic enol formed when ethyl sodioacetoacetate and ethyl ethoxymethyleneacetoacetate are heated together. A mechanism of formation is outlined and supported. The new information is used to prepare various compounds of the xanthyrone class and two of these, 3,3′,3′,5-tetra-acetyl

  根据光谱和化学证据，提出了一种新结构，该结构是将乙二乙酸乙酸乙酯和乙氧基亚甲基乙酰乙酸乙酯一起加热时形成的黄色化合物二乙基黄体烯醇。概述并支持了形成机制。新的信息可用于制备各种an吨酮类化合物，其中3,3'，3'，5-四乙酰基-6-丙烯基-α-吡喃酮和3'-乙酰基-3,3'中的两个5-三乙氧基羰基-6-丙烯基-α-吡喃酮使结构上的竞争者被打折。
• 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME
  申请人：Onco Therapy Science, Inc.

  公开号：US20150005302A1

  公开（公告）日：2015-01-01

  The present invention directs a compound represented by formula (I).

  本发明涉及一种由式(I)所表示的化合物。
• 1,5-naphthyridine derivatives and MELK inhibitors containing the same
  申请人：OncoTherapy Science, Inc.

  公开号：US09067937B2

  公开（公告）日：2015-06-30

  The present invention directs a compound represented by formula (I).

  本发明涉及一种由式(I)表示的化合物。
• Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 4. Identification of an Inhibitor with an Intermediate Duration of Action
  作者：Colin A. Leach、Thomas H. Brown、Robert J. Ife、David J. Keeling、Michael E. Parsons、Colin J. Theobald、Kenneth J. Wiggall

  DOI：10.1021/jm00014a026

  日期：1995.7

  3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this series is developed. Only a limited range of substituents are tolerated on the N-aryl ring or the 6- and 7-positions of the quinoline, and although hydroxylated derivatives were identified possessing markedly greater affinity for the enzyme, none of these proved to have adequate potency after oral dosing. In contrast, the 8-position of the quinoline ring proved suitable for a wide variety of substituents, allowing modification of physicochemical properties while retaining primary activity. This led to the identification of compound 4 (SK&F 97574), which combines good oral potency with a somewhat longer duration of action than 3 (though much shorter than covalent inhibitors such as omeprazole). This compound was selected for further development and evaluation in man.
• Novel 3,6,7-Substituted Pyrazolopyrimidines as Positive Allosteric Modulators for the Hydroxycarboxylic Acid Receptor 2 (GPR109A)
  作者：Clara C. Blad、Jacobus P. D. van Veldhoven、Corné Klopman、Dieter R. Wolfram、Johannes Brussee、J. Robert Lane、Adriaan P. IJzerman

  DOI：10.1021/jm300164q

  日期：2012.4.12

  A number of pyrazolopyrimidines were synthesized and tested for their positive allosteric modulation of the HCA(2) receptor (GPR109A). Compound 24, an efficacious and potent agonist and allosteric enhancer of nicotinic acid's action, was the basis for most other compounds. Interestingly, some of the compounds were found to increase the efficacy of the endogenous ligand 3-hydroxybutyrate and enhance its potency almost 10-fold. This suggests that the pyrazolopyrimidines may have therapeutic value when given alone.